Systemic Therapy for Psoriasis

Systemic Therapy for Psoriasis

Systemic Therapy for Psoriasis

On this page

Systemic Tx Indications - Stepping Up Strategy

  • Indications for Systemic Therapy:

    • Moderate-to-severe plaque psoriasis: BSA > 10%, PASI > 10, or DLQI > 10. (📌 Rule of 10s often cited)
    • Psoriatic Arthritis (PsA): Requires systemic treatment to prevent joint damage.
    • Severe, unstable forms: Erythrodermic psoriasis, generalized pustular psoriasis (GPP).
    • Failure, contraindication, or intolerance to topical therapy and/or phototherapy.
    • Psoriasis in special sites (e.g., face, palms, soles, genitals) if refractory and causing significant QoL impact.
  • Stepping Up Strategy:

⭐ Methotrexate is often the first-line conventional systemic for chronic plaque psoriasis & PsA due to efficacy/cost.

Conventional Agents - Old School Power

  • Methotrexate (MTX)

    • MOA: Antifolate, ↓ DNA synthesis.
    • Dose: 7.5-25 mg weekly. Test 5-10 mg. Folic acid 1-5 mg daily (not MTX day).
    • AEs: Hepatotoxicity, myelosuppression, mucositis, pulmonary fibrosis. Teratogenic.
    • Monitor: CBC, LFTs, renal function.
    • 📌 MTX: Marrow, Teratogen, X-Liver/Lungs/Mucosa.
  • Cyclosporine (CsA)

    • MOA: Calcineurin inhibitor; ↓ IL-2 & T-cell activation. Rapid.
    • Dose: 2.5-5 mg/kg/day.
    • AEs: Nephrotoxicity, HTN, hypertrichosis, gingival hyperplasia, ↑ malignancy.
    • Monitor: BP, Sr.Cr, K+, Mg++, lipids.
    • Use: Severe, erythrodermic, pustular psoriasis. Short-term.
  • Acitretin

    • MOA: Oral retinoid; normalizes keratinocyte differentiation.
    • Dose: 0.3-1 mg/kg/day (e.g., 25-50 mg daily).
    • AEs: Teratogenic (avoid pregnancy 3 years post-Rx!), mucocutaneous dryness, ↑TGs, hepatotoxicity.
    • Monitor: LFTs, lipids, pregnancy tests.
    • Use: Pustular, erythrodermic psoriasis. Good with phototherapy (Re-PUVA).
    • ⭐ Acitretin: Key for pustular psoriasis. ⚠️ Extreme teratogen (contraception 3 years post-Rx).

Biologic Therapies - Targeted Takedown

  • General: mAbs targeting key psoriatic cytokines.
  • Screening (All):
    • TB (QFT/TST, CXR).
    • Hep B, C; HIV.
    • CBC, LFT, KFT.
    • Vaccines (killed only during therapy).
  • TNF-α Inhibitors: (Infliximab, Adalimumab, Etanercept)
    • Target: TNF-α.
    • Risks: Infections (TB), demyelination, lupus, CHF.
    • 📌 Mnemonic: "Eat In Adda" (Etanercept, Infliximab, Adalimumab)
  • IL-17 Inhibitors: (Secukinumab, Ixekizumab, Brodalumab)
    • Target: IL-17A/IL-17RA.
    • Risks: Candidiasis, neutropenia, IBD flare. Brodalumab: ⚠️ Suicidal ideation.
  • IL-12/23 Inhibitor: (Ustekinumab)
    • Target: p40 subunit (IL-12 & IL-23).
    • Risks: Infections.
  • IL-23 Inhibitors (p19 specific): (Guselkumab, Risankizumab, Tildrakizumab)
    • Target: p19 subunit (IL-23).
    • Risks: URI.

Cytokine targets of biologic agents in psoriasis

⭐ TNF-α inhibitors require mandatory screening for latent tuberculosis (LTBI) due to risk of reactivation.

Newer Drugs & Combos - Fresh Frontiers

  • Oral Small Molecules (OSMs): Advancing psoriasis management.
    • Apremilast (Otezla):
      • PDE4 inhibitor; ↑ cAMP, ↓ TNF-α, IL-23, IL-17.
      • Dose: 30 mg BID.
      • Common SE: GI upset, headache (transient). No routine lab monitoring.
    • Deucravacitinib (Sotyktu):
      • Selective TYK2 inhibitor (allosteric); blocks IL-23/IL-12/Type 1 IFN.
      • Dose: 6 mg OD.
      • Superior to Apremilast; fewer JAK-inhibitor class concerns.
    • JAK inhibitors (e.g., Tofacitinib):
      • Primarily for PsA; off-label severe psoriasis.
      • ⚠️ Boxed warning: MACE, VTE, malignancy.

⭐ Deucravacitinib, an oral selective TYK2 inhibitor, uniquely targets the IL-23 pathway with a favorable safety profile compared to pan-JAK inhibitors.

High‑Yield Points - ⚡ Biggest Takeaways

  • Methotrexate: First-line systemic agent, requires folic acid, monitor for hepatotoxicity; teratogenic.
  • Cyclosporine: Offers rapid control, monitor for nephrotoxicity and hypertension.
  • Acitretin: Effective for pustular psoriasis; highly teratogenic (contraception 3 years post-stop).
  • Biologics (TNF-α, IL-17/23 inhibitors): Indicated for moderate-to-severe refractory psoriasis.
  • Apremilast: Oral PDE4 inhibitor, an alternative for moderate psoriasis, fewer monitoring needs.
  • Pre-treatment screening: Essential for latent TB and hepatitis B/C before biologics & methotrexate.
  • Avoid systemic corticosteroids: High risk of rebound pustular psoriasis upon withdrawal.

Practice Questions: Systemic Therapy for Psoriasis

Test your understanding with these related questions

What is the primary condition for which calcitriol is used as a treatment?

1 of 5

Flashcards: Systemic Therapy for Psoriasis

1/10

Tildrakizumab is a monoclonal antibody indicated in moderate-to-severe _____

TAP TO REVEAL ANSWER

Tildrakizumab is a monoclonal antibody indicated in moderate-to-severe _____

plaque psoriasis

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial